A Multi-center, Open-label Study to Investigate the Safety/Tolerability and Efficacy of Ligelizumab (QGE031) in the Treatment of Adult Japanese Patients With Chronic Spontaneous Urticaria (CSU) Inadequately Controlled With H1 Antihistamines

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 14 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ligelizumab (Primary)
Indications Urticaria
Focus Adverse reactions; Registrational
Sponsors Novartis Pharmaceuticals

Most Recent Events

14 Jul 2022 Status changed from active, no longer recruiting to completed.
10 Jan 2022 Planned End Date changed from 11 Feb 2022 to 30 Jan 2022.
10 Jan 2022 Planned primary completion date changed from 11 Feb 2022 to 28 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight